EUVIMEDEUVIMED entdecken
Open Access

Impact of Acute Dopamine Replacement on Cognitive Function in Parkinson's Disease

Joseph Seemiller iD, Christopher Morrow, Jared T Hinkle iD, Kate Perepezko, Vidyulata Kamath iD, Gregory M Pontone, Kelly A Mills iD

Movement Disorders Clinical Practice · 2024

DOI: 10.1002/mdc3.14017 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Movement Disorders Clinical Practice, 2024. Verfasst von Joseph Seemiller und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, Johns Hopkins School of Medicine, Baltimore, Maryland, USA. Hauptthemen laut MEDLINE: Cognition, Executive Function, Parkinson Disease. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 75 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIA NIH HHS, NIMH NIH HHS, NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

PD causes striatal dopaminergic denervation in a posterior/dorsal to anterior/ventral gradient, leaving motor and associative cortico‐striato‐pallido‐thalamic loops differentially susceptible to hyperdopaminergic effects with treatment. As the choice and titration of symptomatic PD medications are guided primarily by motor symptoms, it is important to understand their cognitive implications.

Objective

To investigate the effects of acute dopaminergic medication administration on executive function in Parkinson's disease (PD).

Methods

Participants with idiopathic PD were administered the oral Symbol Digit Modalities Test (SDMT; n = 181) and the Stroop test ( n = 172) in the off‐medication and “best on” medication states. ANCOVA was used to test for differences between off‐medication and on‐medication scores corrected for age and years of education.

Results

After administration of symptomatic medications, scores worsened on the SDMT ( F = 11.70, P < 0.001, d = −0.13), improved on the Stroop color ( F = 26.89, P < 0.001, d = 0.184), word ( F = 6.25, P = 0.013, d = 0.09), and color‐word ( F = 13.22, P < 0.001, d = 0.16) test components, and the Stroop difference and ratio‐based interference scores did not significantly change. Longer disease duration correlated with lower scores on the SDMT, Stroop color, word, and color‐word scores; however, longer disease duration and higher levodopa‐equivalents correlated with higher Stroop difference‐based interference scores.

Conclusions

Symptomatic medication differentially affects performance on two cognitive tests in PD. After acute treatment, core Stroop measures improved, Stroop interference was unchanged, and SDMT performance worsened, likely reflecting complex changes in processing speed and executive function related to acute treatment. When considering motor symptom therapies in PD, an individual's cognitive demands and expectations, especially regarding executive function, should be considered.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

CognitionExecutive FunctionParkinson DiseaseAgedFemaleHumansMaleMiddle AgedAntiparkinson AgentsDopamine AgentsLevodopaNeuropsychological TestsStroop Test

Stichwörter der Autor:innen

Parkinson's diseaseStroop testdopamine overdosesymbol digit modalities test

Substanzen

Antiparkinson AgentsDopamine AgentsLevodopa

Autor:innen und Institutionen

  • Department of Neurology, Johns Hopkins School of Medicine, Baltimore, Maryland, USA.
  • Department of Psychiatry and Behavioral Sciences, Johns Hopkins School of Medicine, Baltimore, Maryland, USA.
  • National Rehabilitation Research & Training Center on Family Support, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.
  • Department of Neurology, University of Florida College of Medicine, Gainesville, Florida, USA.

ORCID-Profile: Joseph Seemiller, Jared T Hinkle, Vidyulata Kamath, Kelly A Mills

Förderung

  • NIA NIH HHS
  • NIMH NIH HHS
  • NIH HHS
  • National Institutes of Health
  • Parkinson's Foundation

Zitieren

APA

Seemiller, J., Morrow, C., Hinkle, J. T., Perepezko, K., Kamath, V., Pontone, G. M., & Mills, K. A. (2024). Impact of Acute Dopamine Replacement on Cognitive Function in Parkinson's Disease. Movement Disorders Clinical Practice. https://doi.org/10.1002/mdc3.14017

Vancouver

Seemiller J, Morrow C, Hinkle JT, Perepezko K, Kamath V, Pontone GM, et al. Impact of Acute Dopamine Replacement on Cognitive Function in Parkinson's Disease. Movement Disorders Clinical Practice. 2024. doi:10.1002/mdc3.14017

BibTeX
@article{Seemiller2024,
  author = {Seemiller, Joseph and Morrow, Christopher and Hinkle, Jared T and Perepezko, Kate and Kamath, Vidyulata and Pontone, Gregory M and Mills, Kelly A},
  title = {Impact of Acute Dopamine Replacement on Cognitive Function in Parkinson's Disease},
  journal = {Movement Disorders Clinical Practice},
  year = {2024},
  doi = {10.1002/mdc3.14017}
}
Kostenlos starten →